Olympus ERCP Scope Claims

Who may qualify?

If you had ERCP and later had an infection, start with the procedure and health records. Ask which device was used and what the tests showed. An infection after care does not by itself prove that a scope caused it.

ERCP is a procedure that uses a scope and x-rays to treat problems in the bile or pancreatic ducts. The special scope is called a duodenoscope. It is not the same device used for every test inside the body. Ask the hospital for the procedure date, scope maker and model instead of assuming any Olympus scope is the one discussed in a safety notice.

Gather records of the infection diagnosis, lab results, treatment and any further hospital stay. Keep any letter the hospital sent about the procedure or device. Make a timeline with dates you know and mark gaps clearly. Ask a lawyer which evidence is needed and which legal rules apply to your situation. This is a way to prepare, not a guarantee that a firm will accept a case.

What could I get?

A safety notice or contamination study does not set a payment for your claim. Ask what evidence is needed for your facts. If there is an actual offer, ask what it covers and which fees or expenses would come out of it.

Keep a government enforcement result separate from an offer to an injured patient. The 2018 DOJ case involved criminal penalties and reporting duties. It was not a payment schedule for every person who had ERCP. Ask whether any offer you are shown is actually made to you and which legal rights you would give up by accepting it.

Before using any figure to plan your finances, ask for the written terms. Ask how the lawyer’s fee is calculated and when expenses are deducted. Ask what disputes or conditions remain before money could be paid. These are questions to raise about an actual proposal, not a prediction of an award.

Is there a deadline?

Ask promptly which filing limit applies to your claim. Bring the procedure date, diagnosis date and any hospital or court notices. Do not wait for every record before asking about the deadline.

Court guidance explains that time limits depend on the law and the type of claim. A date from another person’s case may not apply to yours. Tell the lawyer about any case or claim already filed. Ask which rule controls and what must be done to protect your rights.

A safety-letter date is not automatically your deadline to sue. Nor does reading a notice file a claim for you. Keep the full letter and any envelope or message showing when it arrived. Ask how those facts relate to your procedure, diagnosis and legal options.

What happens after I check?

First clarify the procedure, device and diagnosis. Then ask which records and legal deadlines need a check. Read any written fee and expense terms before hiring a firm.

You can prepare a short timeline for the review. Put the procedure, first symptoms, test results and treatment dates in order. Keep each notice with the event it concerns. Ask which facts support a link to the scope and which other causes need to be considered. A general study cannot answer all of those questions about one person.

Ask who would handle your file and who would represent you if you hire the firm. Ask what the next step requires and what it could cost. Keep a copy of the agreement and any records you send. Do not assume a request for information means a lawsuit has been filed or a payment approved.

Questions people ask

Does infection after ERCP mean the scope was contaminated? Not necessarily. ERCP has several possible complications, and the source of an infection needs a check. Ask the care team about your diagnosis and the evidence.

Does a disposable part mean no cleaning is needed? No. FDA distinguishes fully disposable devices from designs with disposable components. Ask the facility how it follows the instructions for the actual scope and parts used in your care.

How Olympus TJF-Q180V Duodenoscopes Cause Superbug Infections

The Olympus TJF-Q180V duodenoscope, used in endoscopic retrograde cholangiopancreatography (ERCP) procedures to diagnose and treat bile duct and pancreatic conditions, has been linked to outbreaks of carbapenem-resistant Enterobacteriaceae (CRE) and other multidrug-resistant organisms. The device's complex elevator mechanism — a small wire-controlled lever at the instrument's distal tip — creates microscopic crevices that trap biological material and harbor bacteria even after the manufacturer's recommended reprocessing (high-level disinfection) protocols are followed. Patients undergoing ERCP with contaminated duodenoscopes are exposed to life-threatening infections that resist last-resort antibiotics.

Elevator Mechanism Bacterial Entrapment

The TJF-Q180V's distal tip contains a small elevator mechanism used to guide catheters and wires into the bile duct during ERCP. This elevator sits within a sealed channel with microscopic gaps between the elevator lever, its housing, and the surrounding O-ring seals. During procedures, patient fluids — bile, blood, and tissue debris — are forced into these crevices under hydraulic pressure. The gaps are too narrow for cleaning brushes to reach and too complex for chemical disinfectants to fully penetrate, creating a persistent bacterial reservoir that transfers organisms from patient to patient.

Reprocessing Protocol Failure

Olympus's FDA-cleared reprocessing instructions required manual brushing followed by automated high-level disinfection (HLD). However, the elevator channel's geometry makes complete manual cleaning physically impossible — studies have demonstrated that even meticulous adherence to Olympus's protocol leaves residual biological material and viable bacteria in the elevator mechanism. The FDA found that Olympus's reprocessing instructions were never clinically validated to achieve sterilization of the elevator channel, meaning the manufacturer marketed a device with cleaning instructions it knew or should have known were inadequate.

CRE and Multidrug-Resistant Organism Transmission

Carbapenem-resistant Enterobacteriaceae (CRE) — sometimes called 'nightmare bacteria' by the CDC — are gram-negative organisms resistant to carbapenems, the antibiotics of last resort. When CRE colonize a duodenoscope's elevator mechanism, subsequent patients undergoing ERCP with that instrument can have the organisms directly introduced into their bile duct, an anatomically privileged site with limited immune surveillance. CRE bloodstream infections carry mortality rates of 40-50%, and treatment options are extremely limited.

Biofilm Formation in Device Channels

Once bacteria colonize the elevator mechanism's crevices, they form biofilms — structured communities of microorganisms encased in a protective extracellular matrix. Biofilms are orders of magnitude more resistant to chemical disinfection than free-floating bacteria. Once established in a duodenoscope, biofilms can persist through hundreds of reprocessing cycles, continuously seeding new infections. Standard high-level disinfection protocols were not designed to eliminate established biofilms in complex medical device channels.

Scope-to-Patient Cross-Contamination Chain

The transmission chain is direct and traceable: contaminated duodenoscope is used on Patient A, reprocessed according to manufacturer instructions, then used on Patient B who develops CRE infection with the same bacterial strain (confirmed by whole-genome sequencing). CDC and hospital epidemiology investigations at UCLA, Virginia Mason, and other facilities established definitive scope-to-patient transmission chains, ruling out other infection sources and confirming the duodenoscope as the vector.

• Sealed Elevator Design Defect: The TJF-Q180V's elevator mechanism was designed with a sealed distal tip that prevented visual inspection and effective mechanical cleaning of internal crevices — a fundamental design choice that prioritized device longevity over patient safety and created an inherent infection risk that no reprocessing protocol could fully mitigate.
• Inadequate and Unvalidated Reprocessing Instructions: Olympus provided reprocessing instructions that were never clinically validated to achieve sterilization of the elevator channel. The FDA later determined that the instructions were insufficient, but Olympus continued marketing the device with the same cleaning protocol for years after outbreaks were reported.
• CRE Lethality and Antibiotic Resistance: The organisms transmitted by contaminated duodenoscopes — particularly CRE — carry mortality rates of 40-50% for bloodstream infections and are resistant to nearly all available antibiotics. Patients who survive CRE infections often face prolonged hospitalization, organ damage, and permanent health consequences.
• Olympus Market Dominance Limiting Alternatives: Olympus controlled approximately 85% of the global duodenoscope market, meaning hospitals had few viable alternatives even after infection risks were documented. This market dominance meant contaminated devices remained in clinical use at thousands of facilities while Olympus resisted design changes.
• Delayed Disclosure of Known Risks: Internal Olympus documents and regulatory correspondence indicate the company was aware of duodenoscope-linked infection reports in Europe years before U.S. outbreaks became public. Olympus did not proactively warn U.S. hospitals or the FDA, delaying corrective action that could have prevented infections and deaths.
• Vulnerable Patient Population: ERCP procedures are performed on patients with serious hepatobiliary and pancreatic conditions — many of whom are already immunocompromised, elderly, or critically ill. These patients are least able to withstand CRE superinfection, amplifying the consequences of device contamination.
• The elevator mechanism design of the TJF-Q180V creates crevices that cannot be adequately cleaned by manual or automated reprocessing, as confirmed by FDA testing and independent microbiological studies.
• CDC outbreak investigations at multiple hospitals established definitive duodenoscope-to-patient CRE transmission chains using whole-genome sequencing.
• Olympus's reprocessing instructions were inadequate to prevent bacterial transmission — the FDA issued multiple safety communications confirming this finding.
• The October 2025 Olympus Urgent Field Safety Notice updated reprocessing training and inspection materials and reported 2 deaths and 5 serious injuries from infection or positive culture potentially related to the duodenoscope since 2024. Olympus said the death and injury reports did not contain sufficient information to determine whether the duodenoscope contributed to an infection.
• Transition to fully disposable or disposable-tip duodenoscopes is the only reliable way to eliminate cross-contamination risk from elevator mechanism bacterial entrapment.

The Olympus duodenoscope litigation is fundamentally a design defect and failure-to-warn case. The core claim is that Olympus designed and marketed a reusable medical device with an elevator mechanism it knew could not be adequately cleaned, provided reprocessing instructions it knew were insufficient, concealed known infection risks from hospitals and the FDA, and failed to redesign the device or transition to disposable components despite years of documented superbug outbreaks. In October 2025 Olympus issued a field safety notice updating its reprocessing training and inspection materials.

Regulatory Actions Against Olympus Duodenoscopes

The Olympus TJF-Q180V duodenoscope has been the subject of extensive FDA regulatory action, congressional investigation, CDC outbreak responses, and a landmark Department of Justice criminal prosecution. The regulatory record documents a pattern of known contamination risks, delayed manufacturer response, and ongoing patient safety failures spanning more than a decade.